Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

V. Moreno; M. Gil-Martin; M. Johnson; R. Aljumaily; P. Lopez Criado; D. W. Northfelt; M. Crittenden; S. Jabbour; L. Rosen; P. Garrido Lopez; A. Hervás Morón; P. Rietschel; K. K. Mohan; J. Li; E. Stankevich; T. Rowlands; M. Feng; I. Lowy; M. G. Fury

doi:10.1093/annonc/mdy288.035

Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

V. Moreno, M. Gil-Martin, M. Johnson, R. Aljumaily, P. Lopez Criado, D. W. Northfelt, M. Crittenden, S. Jabbour, L. Rosen, P. Garrido Lopez, A. Hervás Morón, P. Rietschel, K. K. Mohan, J. Li, E. Stankevich, T. Rowlands, M. Feng, I. Lowy, M. G. Fury

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii414
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy288.035
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy288.035

Cite this

Moreno, V., Gil-Martin, M., Johnson, M., Aljumaily, R., Lopez Criado, P., Northfelt, D. W., Crittenden, M., Jabbour, S., Rosen, L., Garrido Lopez, P., Hervás Morón, A., Rietschel, P., Mohan, K. K., Li, J., Stankevich, E., Rowlands, T., Feng, M., Lowy, I., & Fury, M. G. (2018). Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii414. https://doi.org/10.1093/annonc/mdy288.035

Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). / Moreno, V.; Gil-Martin, M.; Johnson, M. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii414.

Research output: Contribution to journal › Article › peer-review

Moreno, V, Gil-Martin, M, Johnson, M, Aljumaily, R, Lopez Criado, P, Northfelt, DW, Crittenden, M, Jabbour, S, Rosen, L, Garrido Lopez, P, Hervás Morón, A, Rietschel, P, Mohan, KK, Li, J, Stankevich, E, Rowlands, T, Feng, M, Lowy, I & Fury, MG 2018, 'Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii414. https://doi.org/10.1093/annonc/mdy288.035

Moreno V, Gil-Martin M, Johnson M, Aljumaily R, Lopez Criado P, Northfelt DW et al. Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii414. doi: 10.1093/annonc/mdy288.035

@article{f66c41a562554943921bf81fca2811a6,

title = "Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)",

author = "V. Moreno and M. Gil-Martin and M. Johnson and R. Aljumaily and {Lopez Criado}, P. and Northfelt, {D. W.} and M. Crittenden and S. Jabbour and L. Rosen and {Garrido Lopez}, P. and {Herv{\'a}s Mor{\'o}n}, A. and P. Rietschel and Mohan, {K. K.} and J. Li and E. Stankevich and T. Rowlands and M. Feng and I. Lowy and Fury, {M. G.}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy288.035",

language = "English (US)",

volume = "29",

pages = "viii414",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC)

T2 - Results from a phase I expansion cohort (EC 2)

AU - Moreno, V.

AU - Gil-Martin, M.

AU - Johnson, M.

AU - Aljumaily, R.

AU - Lopez Criado, P.

AU - Northfelt, D. W.

AU - Crittenden, M.

AU - Jabbour, S.

AU - Rosen, L.

AU - Garrido Lopez, P.

AU - Hervás Morón, A.

AU - Rietschel, P.

AU - Mohan, K. K.

AU - Li, J.

AU - Stankevich, E.

AU - Rowlands, T.

AU - Feng, M.

AU - Lowy, I.

AU - Fury, M. G.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081588797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081588797&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy288.035

DO - 10.1093/annonc/mdy288.035

M3 - Article

C2 - 32137038

SN - 0923-7534

VL - 29

SP - viii414

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this